Titles
- E-Mail from Joshua Lederberg to Nancy A. Forbes1
- E-Mail from Joshua Lederberg to Petros Tsipouras1
- E-Mail from Joshua Lederberg to Richard Perle1
- E-Mail from Joshua Lederberg to Robert Ursano1
- E-Mail from Joshua Lederberg to Sam Gubins1
- E-Mail from Joshua Lederberg to Stephen E. Levick1
- E-Mail from Joshua Lederberg to William Winkenwerder and Brian Hughes [on terms of reference for a SARS quarantine policy task force]1
- E-Mail from Roger Gibson to Joshua Lederberg1
- E-mail from Joshua Lederberg to Frederick Burkhardt1
- E-mail from Joshua Lederberg to John Hamre1
- E-mail from Joshua Lederberg to Juan M. Campanario1
- E-mail from Joshua Lederberg to Seymour S. Cohen [on Erwin Chargaff memoir]1
- E-mail from Joshua Lederberg to Ute Hentschel and Michael Steinert1
- E-prescribing in California: why aren't we there yet?1
- E11(R1) addendum: clinical investigation of medicinal products in the pediatric population1
- E14 and S7B clinical and nonclinical evaluation of QT/QTc interval prolongation and proarrhythmic potential: questions and answers1
- E14 clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs--questions and answers (R3)1
- E17 general principles for planning and design of multiregional clinical trials1
- E18 genomic sampling and management of genomic data1
- E19: a selective approach to safety data collection in specific late-stage preapproval or post-approval clinical trials : guidance for industry1